Generic Medicine Info
May be taken with or without food.
Pregnancy. Concomitant use w/ ketoconazole and itraconazole.
Special Precautions
Avoid abrupt withdrawal. Hepatic and renal impairment. Elderly, small or debilitated patients. Lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor resp and CV status; CBC and urinalysis periodically during prolonged use.
Adverse Reactions
Somnolence, hypokinesia, dizziness, abnormal coordination; allergic reaction, chills, fever, neck pain, upper extremity pain; flushing palpitation; constipation, dry mouth, decreased/increased appetite, flatulence, gastritis, vomiting; thirst; arthritis, muscle spasm, myalgia; anxiety, agitation, amnesia, apathy, emotional lability, euphoria, hostility, paraesthesia, seizure, sleep disorder, stupor, twitch; asthma, cough, dyspnoea, rhinitis, sinusitis; rash, sweating, urticaria; abnormal vision, ear pain; eye irritation, pain, swelling; perverse taste, photophobia, tinnitus; frequent urination, menstrual cramps, urinary hesitancy/urgency, vag discharge/itching. Rarely, jaw pain, oedema, swollen breast; arrhythmia, syncope; enterocolitis, melaena, mouth ulceration; thyroid nodule; leucopenia, swollen lymph nodes, purpura; increased SGOT, wt gain/loss; arthralgia; ataxia, circumoral paraesthesia, decreased libido and reflexes, hallucinations, neuritis, tremor, nystagmus; epistaxis, hyperventilation, laryngitis; acne, dry skin; decreased hearing, scotomata, diplopia; haematuria, nocturia, oliguria, penile discharge, urinary incontinence.
Potentially Fatal: Anaphylaxis.
Drug Interactions
Increased plasma concentration w/ CYP3A inhibitors (e.g. nefazodone, fluvoxamine, erythromycin). Decreased plasma concentration w/ CYP3A inducers (e.g. carbamazepine, phenytoin, rifampicin, barbiturates). Additive effect w/ other CNS depressant drugs.
CIMS Class
Hypnotics & Sedatives
ATC Classification
N05CD04 - estazolam ; Belongs to the class of benzodiazepine derivatives. Used as hypnotics and sedatives.
Disclaimer: This information is independently developed by CIMS based on estazolam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in